Skip to content

Lower Limb ExoNET: Development and Evaluation for Gait Assistance With Stroke Survivors

Lower Limb ExoNET: Development and Evaluation for Gait Assistance With Stroke Survivors

Status
Not yet recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06999213
Enrollment
20
Registered
2025-05-31
Start date
2026-01-31
Completion date
2029-12-31
Last updated
2025-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Stroke-related gait impairments, such as poor limb coordination, imbalance, and reduced push-off strength, are often addressed using robotic systems or electrical stimulation, which can be costly, invasive, or insufficient for long-term recovery. Current devices often assist movement but fail to promote functional motor learning. Research supports rehabilitation strategies that amplify gait errors to drive neuroplasticity and adaptation. The LegExoNET (Exoskeletal Network for Elastic Torque) is a novel, passive wearable exoskeleton designed to address this need by enabling both assistive and therapeutic gait training. It stores and releases elastic energy to aid movement while allowing natural joint motion. The system aims to support individuals post-stroke transitioning to independent rehabilitation by offering a lightweight, affordable, and adaptive solution. Initial testing will focus on healthy individuals to assess safety and feasibility before expanding to stroke populations. The LegExoNET has the potential to enhance gait recovery and reduce therapist burden through error augmentation and personalized support, both in clinical and at-home settings.

Interventions

OTHERAssist

The device will provide assistive torques to support either ankle, knee, and/or hip movements.

OTHERResist

The device will apply resistive torques to exaggerate gait asymmetries, facilitating error augmentation.

OTHERSlack

The device will be worn but will not generate any torque.

Sponsors

Shirley Ryan AbilityLab
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

All participants will receive either intervention, but the order in which they receive it will be randomized.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-70 years old * Ability to provide informed consent * Capable of ambulating without the use of assistive devices for 2 hours

Exclusion criteria

* History of stroke, SCI, or other neurological medical diagnoses * Pregnant * Severe medical diagnoses (e.g. cardiovascular, orthopedic) * Skin allergies or irritation; open wounds * Prisoners * Cognitively impaired adults

Design outcomes

Primary

MeasureTime frameDescription
Electromyography (EMG) amplitude during walking under each intervention conditionDay 1 (single study visit); Measured during each intervention condition (Assist, Resist, Sham)Muscle activation (specifically voltage amplitude) using wearable surface EMG of the gastrocnemius, lateral gastrocnemius, tibialis anterior, soleus, biceps femoris, rectus femoris, and gluteus maximus.

Secondary

MeasureTime frameDescription
6 Minute Walk TestDay 1 (single study visit); Measured during each intervention condition (Assist, Resist, Sham)* The score of the test is the distance a patient walks in 6 minutes. Walking is self-paced on a standardized walk space using standardized instructions. * The patient may take as many standing rests as they like, but the timer should kept running and the number of rests taken and the total rest time recorded. * Assistive devices are allowed and must be documented. * Clinician assistance is permitted and must be from posterior so as not to pace the participant, and the level of assist must be documented. * When administering the test, do not walk in front of or directly beside the patient, as this may pace the patient and influence the speed and distance they walk. Instead, walk at least a half step behind the patient. * If a participant cannot walk but has goals and expectations to regain walking, a 6MWT score of 0 should be documented. * No talking should be done with the participant during the test other than the scripted and timed feedback outlined in the 6MWT guidelines.
10 Meter Walk TestDay 1 (single study visit); Measured during each intervention condition (Assist, Resist, Sham)The individual is instructed to walk a set distance (6 meters, 10 meters, etc). Time is measured while the individual walks the set distance (often the individual is given space to accelerate to his/her preferred walking speed (this distance is not included when determining speed). The distance covered is divided by the time it took the individual to walk that distance.
Gait SymmetryDay 1 (single study visit); Measured during each intervention condition (Assist, Resist, Sham)Collect gait symmetry and other gait parameters such as stride length, using Kinect v2, GaitRite, and OpenCap. Kinect v2 tracks 3D joint kinematics to assess symmetry (left-right differences), stride length (foot displacement), and parameters like step time and velocity. GaitRite's pressure-sensitive walkway measures precise stride length, symmetry (step length/time differences), and parameters such as cadence and stance time. OpenCap, with multiple cameras and cloud processing, captures 3D kinematics to calculate symmetry, stride length, joint angles, and the Gait Deviation Index (GDI). Data will be synchronized, systems calibrated, and participants will walk naturally for analysis using dedicated software and scripts, ensuring comprehensive gait evaluation.

Contacts

Primary ContactMarc Camardo
mcamardo@sralab.org224-422-7182

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026